Please login to the form below

Not currently logged in
Email:
Password:

lumateperone

This page shows the latest lumateperone news and features for those working in and with pharma, biotech and healthcare.

Intra-Cellular soars on FDA approval of schizophrenia drug

Intra-Cellular soars on FDA approval of schizophrenia drug

Shares in the company rocketed over 178% yesterday as the news broke, after the FDA approved Caplyta (lumateperone) as a treatment for schizophrenia in adults.

Latest news

  • Intra-Cellular plans schizophrenia filing in 2018 Intra-Cellular plans schizophrenia filing in 2018

    Says lumateperone could provide additional benefits over existing treatments. US biotech company Intra-Cellular Therapies says it could file its lead drug lumateperone for schizophrenia as early as next year after ... Lumateperone is backed by two phase

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...